Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease

Condition(s) studied

Investigational drug(s) / intervention(s)

High-intensity interval training: High-intensity interval training

Moderate intensity exercise training: Moderate intensity exercise training

Low intensity exercise training: Low intensity exercise training

Study summary

Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity. Conversely, MASLD histological remission though diet or metabolic surgeries is also linked to a decrease in muscle fat content. Therefore, skeletal muscle appears as a potential target to treat MASLD.

Eligibility

Primary outcome measure(s)

• the impact of physical activity on muscle and liver phenotypes — every four weeks from baseline till study completion
  the investigators will assess at baseline and every four weeks till study completion the impact of intervention on liver phenotype assessed by transient elastography and muscle phenotype assessed by MRI

Trial sites (2)

More Cliniques universitaires Saint-Luc- Université Catholique de Louvain trials in Belgium

Other trials for the same condition